XORTX Therapeutics Inc. XRTX

XORTX Therapeutics plans FDA IND submission for XRx-026 gout program using XORLO, targeting over $700M US gout market. Planned FDA IND submission for new gout treatment targets large market and represents major strategic move.

XORTX Therapeutics Inc. initiates clinical and commercial manufacturing of XORLO™. Manufacturing start advances XORLO™ toward commercialization and potential revenue for XORTX.

XORTX Therapeutics Inc. (XRTX) elects to voluntarily delist from the TSX Venture Exchange. Voluntary delisting from TSX Venture Exchange reduces trading access, liquidity and investor reach for XORTX Therapeutics Inc.

XORTX Therapeutics Inc. closed a US$5 million public offering. The capital infusion improves XORTX's cash position and supports continued R&D and operations.

XORTX Therapeutics Inc. has announced a USD $3 million offering to support its operations and development initiatives. The offering is expected to enhance the company's financial position and facilitate ongoing projects. Details regarding the terms of the offering and its intended use of proceeds have been outlined, indicating a strategic move to bolster the company's resources. The offering is expected to provide necessary funding for operations and development, which may moderately influence financial performance.

XORTX Therapeutics Inc. raised $5 million via public offering with E.F. Hutton & Co. serving as exclusive placement agent. The $5 million public offering supplies XORTX Therapeutics Inc. with fresh capital to fund operations.

XORTX Therapeutics Inc. (XRTX) announces a US$5 million public offering. $5 million public offering provides funding for operations and clinical trials but dilutes shareholders, moderately affecting financial health and market sentiment.

XORTX Therapeutics Inc. (XRTX) meets Nasdaq continued listing requirements, ensuring ongoing compliance and exchange trading eligibility. Meeting Nasdaq listing requirements avoids delisting risk, significantly boosting investor confidence and stock liquidity.

XORTX Therapeutics Inc. (XRTX) announces closing of acquisition of Vectus Kidney Anti-fibrotic Asset. Closing acquisition of kidney anti-fibrotic asset represents major strategic expansion of XORTX's pipeline in core kidney disease focus.

XORTX Therapeutics Inc. has provided an update regarding its acquisition of a renal anti-fibrotic therapeutic program from Vectus Biosystems. This strategic move aims to enhance XORTX's portfolio in addressing kidney-related diseases, potentially positioning the company for future growth in the renal therapeutics market. The acquisition of a renal anti-fibrotic program is a significant strategic move that could enhance XORTX's product offerings and market position.

XORTX Therapeutics Inc. announced that recent published research supports its approach to treating gout. The findings bolster the company's strategy and may enhance its credibility in the market as it seeks to advance its therapeutic solutions for gout management. The research findings may positively influence XORTX's competitive positioning and product innovation in the gout treatment market.

XORTX Therapeutics Inc. announced groundbreaking research focused on genome-wide pathogenic pathways related to gout, highlighting its commitment to advancing understanding and treatment of the condition. The company also provided a corporate update, indicating progress in its strategic initiatives and research efforts. The research on pathogenic pathways in gout could significantly enhance product development and market positioning for XORTX.

XORTX Therapeutics Inc. has successfully closed a registered direct offering, raising US$1.1 million. The offering involved the sale of common shares and warrants to institutional investors, with proceeds intended to support the company's ongoing development initiatives. The capital raised will support ongoing development efforts, potentially influencing financial performance and product innovation.

XORTX Therapeutics Inc. has issued a correction notice and announced a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement. This extension provides the company additional time to meet the necessary criteria to maintain its listing on the exchange. The extension to regain compliance with Nasdaq could moderately influence investor sentiment and operational focus.

XORTX Therapeutics Inc. (XRTX) experienced a 45% surge in stock price following the announcement of a US$3 million deal to acquire a renal program from Vectus Biosystems. This acquisition is expected to enhance XORTX's portfolio and capabilities in developing treatments for kidney diseases, signaling a strategic move to strengthen its market position. The acquisition of a renal program is a significant strategic move that could enhance product offerings and market positioning.

XORTX Therapeutics Inc. has announced the acquisition of a renal anti-fibrotic therapeutic program from Vectus Biosystems. This strategic move aims to enhance XORTX's portfolio in addressing kidney diseases, potentially leading to advancements in treatment options and market positioning. Acquiring a therapeutic program can significantly impact XORTX's product offerings and competitive positioning in the renal disease market.

XORTX Therapeutics Inc. is experiencing a rise in premarket trading as it begins the preparation for an Investigational New Drug (IND) application for XORLO, a treatment aimed at gout. This move is part of the company's ongoing efforts to advance its product pipeline and address unmet medical needs in gout management. Initiating IND preparation for XORLO represents a significant strategic move that could enhance the company's market position and investor sentiment.

XORTX Therapeutics Inc. has initiated the preparation for an Investigational New Drug (IND) application for XORLO™, a treatment aimed at addressing gout. This step is part of the company's ongoing efforts to advance its gout program, which is expected to enhance its product pipeline and potentially improve patient outcomes in this therapeutic area. Initiating IND preparation for XORLO™ represents a significant strategic move that could impact the company's future performance and market positioning.

XORTX Therapeutics Inc. provided an update on its corporate activities and outlined plans for 2025 and 2026, focusing on advancing its therapeutic programs and potential collaborations. The company aims to enhance its product pipeline and strengthen its market position through strategic initiatives and research developments. Significant strategic moves and planned activities are expected to impact the company's future performance and market positioning.

XORTX Therapeutics Inc. announced a private placement of USD $114,500 to support its operations and development initiatives. The funds will be used to advance the company's research and product pipeline, focusing on treatments for kidney diseases. This financing is part of XORTX's strategy to enhance its financial position and operational capabilities. The private placement provides necessary funding that may support product development and operational stability.

XORTX Therapeutics Inc. has successfully completed a non-brokered private placement of units, raising a total of $1.5 million. The offering consisted of 3 million units priced at $0.50 each, with each unit comprising one common share and one-half of a common share purchase warrant. The funds raised will be utilized for general corporate purposes and to advance the company's clinical programs. The company has also announced that it will pay finders' fees to certain parties involved in the placement. The private placement provides necessary funding for clinical programs, which could moderately influence financial performance and market sentiment.

XORTX Therapeutics Inc. announced a non-brokered private placement to raise up to USD $925,000 by issuing up to 1,267,123 common share units at USD $0.73 per unit. Each unit includes one common share and one warrant, allowing the purchase of an additional share at USD $1.20 for 60 months. The offering is available to Canadian residents, excluding Quebec, and will not have a hold period under Canadian securities laws. Proceeds will support XORTX's gout and kidney disease programs. The closing date is expected around July 4, 2025, pending necessary approvals. The private placement will provide funding to advance key therapeutic programs, potentially impacting financial performance.

XORTX Therapeutics Inc. has received guidance from the FDA regarding the next steps for filing a new drug application (NDA) for its gout treatment, XORLO™. The Type B meeting clarified necessary actions, including finalizing meeting minutes, preparing an Investigational New Drug application, and characterizing pharmacokinetics. XORTX aims to submit the NDA in the first half of 2026, emphasizing the importance of this therapeutic option for gout patients. Approximately 44 million individuals in the US have elevated uric acid levels, with gout affecting 9.2 million. The company is focused on advancing its XRx-026 program to address unmet medical needs in gout treatment. The FDA's guidance and the planned NDA filing for XORLO™ represent significant strategic moves that could alter XORTX's market position and investor sentiment.

XORTX Therapeutics Inc. announced the granting of a European patent for its proprietary xanthine oxidase inhibitor formulations aimed at treating gout and autosomal dominant polycystic kidney disease. The patent enhances XORTX's intellectual property portfolio in the EU and supports its first-in-class gout program, addressing health issues related to hyperuricemia. With this patent, XORTX now holds five patents in the US and EU for uric acid-lowering agents, which could lead to commercialization and partnership opportunities in Europe. The patent grant significantly strengthens XORTX's market position and potential for product commercialization in Europe.

XORTX Therapeutics Inc. announced an upcoming Type B meeting with the FDA to discuss the XRx-026 program for gout treatment, aiming to confirm its readiness for a New Drug Application (NDA) submission. The meeting package will be submitted next week, with FDA feedback expected by April 26, 2025. CEO Dr. Allen Davidoff expressed optimism about advancing the program, which could provide a new therapeutic option for gout patients and potentially lead XORTX to a revenue-positive state. The company is also developing other products targeting kidney diseases. The FDA meeting could significantly influence the approval process and market entry of a new gout treatment, impacting XORTX's future performance.

XORTX Therapeutics Inc. has requested a Type C meeting with the FDA to discuss the XRx-026 program for gout treatment, aiming to accelerate the submission of a New Drug Application for its proprietary formulation, XORLO™. The meeting will assess the program's readiness for marketing approval under the FDA’s 505(b)2 pathway. CEO Dr. Allen Davidoff highlighted the potential for XORLO™ to address unmet medical needs in gout patients, particularly those intolerant to existing treatments. Approximately 9.2 million individuals in the US suffer from symptomatic gout, which is linked to various serious health conditions. Updates on the program's progress will be provided as available. The FDA meeting could significantly impact the approval timeline and market entry of XORLO™, influencing investor sentiment and company trajectory.

XORTX Therapeutics Inc. announced its participation in the Microcap Conference from January 28 to 30, 2025, in Atlantic City, NJ. The company will present its plans for the XRx-026 gout program and the XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD). CEO Dr. Allen Davidoff emphasized the opportunity to engage with investors and discuss the company's strategies for advancing its drug programs towards FDA marketing approval. The presentation will be recorded and made available on the company's website. The presentation at a significant investment conference and the focus on advancing drug programs could significantly influence investor sentiment and the company's trajectory.

XORTX Therapeutics Inc. (XRTX) adds late stage gout program to pipeline. The addition of a late stage gout program to XORTX's pipeline is a significant strategic move that could alter the company's trajectory and investor sentiment.

XORTX Therapeutics Inc. (XRTX) strengthens executive team. The addition of new executives may moderately influence key areas such as strategic decision-making and operational efficiency.

XORTX Therapeutics Inc. presented a study on the health consequences of high uric acid and xanthine oxidase in polycystic kidney disease at the American Society of Nephrology. The study results could significantly impact XORTX's future treatment strategies and market positioning.